sertraline has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bitcover, R; Drinberg, V; Peer, D; Rajchenbach, W | 1 |
| Bar, M; Gil-Ad, I; Lomnitski, L; Luria, D; Ram, E; Taler, M; Weizman, A; Zolokov, A | 1 |
2 other study(ies) available for sertraline and Adenocarcinoma
| Article | Year |
|---|---|
Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Nanomedicine; Ovarian Neoplasms; Polyethylene Glycols; Random Allocation; Sertraline; Xenograft Model Antitumor Assays | 2014 |
Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice.
Topics: Adenocarcinoma; Animals; Antidepressive Agents; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Paroxetine; Sertraline; Xenograft Model Antitumor Assays | 2008 |